We showed that second-line treatment with everolimus may affect mesenchymal cancer cell differentiation and angiogenesis recovery following acquisition of sunitinib resistance; tumors of mice treated with everolimus also had decreased vimentin and increased E-cadherin expression. The gene discussed is VIM; the disease is cancer.